However, stratification of the cohort by BMI, revealed a significant association between the presence of CD32B + B-CLS and reduced time to metastatic disease in patients with BMI ≥ 25 kg/m2 (p = 0.009) but not with BMI < 25 kg/m2 (p = 0.779) (Fig. 5b,c). The gene discussed is FCGR2B; the disease is metastatic neoplasm.